Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
- None.
- None.
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update.
The event will be webcast live under the “Events” section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days.
Dial-in information for conference participants may be obtained by registering for the event here.
About Design Therapeutics
Design Therapeutics is a biotechnology company developing a new class of therapies based on its platform of GeneTAC™ gene targeted chimera small molecules. The company’s GeneTAC™ molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its lead GeneTAC™ small molecule, DT-216, in development for patients with Friedreich ataxia, the company is advancing programs in Fuchs endothelial corneal dystrophy and myotonic dystrophy type-1. Discovery efforts for multiple other serious genetic disorders are also underway. For more information, please visit designtx.com.
Contact:
Investors:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When will Design Therapeutics, Inc. (DSGN) host the conference call and webcast?
What is the purpose of the conference call and webcast by Design Therapeutics, Inc. (DSGN)?
Where can the webcast be accessed?
How long will the replay of the webcast be available?
How can conference participants obtain dial-in information?
